MAP 2021 Virtual
![Ton N. Schumacher](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/ton-n.-schumacher/9431304-2-eng-GB/ton-n.-schumacher_i770.jpg)
Using ex vivo avatars to understand immune reactivation in cancer
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
![Steffen Böttcher](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/steffen-boettcher/9431292-1-eng-GB/steffen-boettcher_i770.jpg)
CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
![Johanna Joyce](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/johanna-joyce/9431139-1-eng-GB/johanna-joyce_i770.jpg)
Which immune cell type is it best to target therapeutically in brain tumours?
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system
![Poster area_05](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/poster-area_05/9433770-1-eng-GB/poster-area_05_i770.jpg)
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
![Delegates walking 3](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/delegates-walking-3/9143766-1-eng-GB/delegates-walking-3_i770.png)
Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
![Poster area_03](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/poster-area_03/9433746-1-eng-GB/poster-area_03_i770.jpg)
Next-generation sequencing of circulating tumour DNA can optimise clinical trial recruitment
Molecular pre-screening identified targetable alterations in patients with unknown genomic drivers
![Poster area_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/poster-area_01/9433722-1-eng-GB/poster-area_01_i770.jpg)
Pathogenic germline variants are more common than ‘incidental’
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information
![Public 3](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-3/9144006-1-eng-GB/public-3_i770.jpg)
How can exosome research improve patient management?
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic
![Public 6](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-6/9274557-1-eng-GB/public-6_i770.jpg)
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report
![Clinical trial_Design](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-stock/clinical-trial_design/9437961-1-eng-GB/clinical-trial_design_i770.jpg)
Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies